Jian C, Zhao A, Ma X, et al. - In this population-based cross-sectional study involving 641 individuals, researchers assessed the efficacy of saliva 1,5-anhydroglucitol (1,5-AG) in diabetes screening in a Chinese population. From September 2018 to June 2019, individuals without a valid diabetic history were recruited. Compared with individuals who did not have DM, saliva 1,5-AG levels in patients with DM were lower. Saliva 1,5-AG was positively correlated with serum 1,5-AG and negatively related to blood glucose and glycated hemoglobin (HbA1c). The efficiency of diabetes screening was improved by saliva 1,5-AG combined with FPG or HbA1c. Saliva 1,5-AG is robust for nonfasting measurements and is a noninvasive and convenient tool for screening of diabetes.